Tyk2-IN-13
Modify Date: 2024-04-03 17:42:36
Tyk2-IN-13 structure
|
Common Name | Tyk2-IN-13 | ||
|---|---|---|---|---|
| CAS Number | 2775417-67-7 | Molecular Weight | 578.63 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C29H30D3N7O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Tyk2-IN-13Tyk2-IN-13 (compound 30) is an orally active TYK2 inhibitor. Tyk2-IN-13 inhibits IFNα stimulated STAT3 phosphorylation with an IC50 value of 1.90 nM. Tyk2-IN-13 can be used for the research of autoimmune diseases[1]. |
| Name | Tyk2-IN-13 |
|---|
| Description | Tyk2-IN-13 (compound 30) is an orally active TYK2 inhibitor. Tyk2-IN-13 inhibits IFNα stimulated STAT3 phosphorylation with an IC50 value of 1.90 nM. Tyk2-IN-13 can be used for the research of autoimmune diseases[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-6:33 nM (IC50) IL-2:41 nM (IC50) |
| In Vitro | Tyk2-IN-13 (0-10 μM; 1.5 h) shows inhibitory effect to IFNα stimulated STAT3 phosphorylation with an IC50 value of 1.90 nM[1]. Tyk2-IN-13 (0.244-1000 nM; 30 min) exhibits binding affinities with IC50s of 3496, 41 and 33 nM for EPO, 1L-2 and 1L-6, respectively[1]. |
| In Vivo | Tyk2-IN-13 (30 mg/kg; p.o. BID for 6 days) decreases the colonic weight of colitis mice[1]. Tyk2-IN-13 (20 mg/kg; p.o. BID for 5 days) weakens IL-23-induced acanthosis in vivo[1]. Animal Model: Male CB17-SCID mice with IL-23-dependent colitis[1] Dosage: 30 mg/kg Administration: Oral gavage; 30 mg/kg; twice daily for 6 days Result: Showed a decreasing effect in colonic weight, and no significant difference was observed relative to deucravacitinib. Animal Model: Female C57BL/6 mice with psoriasis-like skin inflammation[1] Dosage: 20 mg/kg Administration: Oral gavage; 20 mg/kg; twice daily for 5 days Result: Significantly protected mice from IL-23-induced acanthosis with no significant weight losses, and showed comparable results with deucravacitinib. |
| References |
| Molecular Formula | C29H30D3N7O6 |
|---|---|
| Molecular Weight | 578.63 |